CG Oncology Inc.
CGON
Updated: 24/09/2026, 15:27:35
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Irvine, California.
No summaries found.
- Share price
- $73.36
- Market cap
- $6.47B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Arthur Kuan
- Employees
- 142
- IPO date
- 25/01/2024
- Beta
- 0.237
- Last dividend
- $0.00
- Day range
- $71.86 – $77.79
- 52-week range
- $35.64 – $80.97
- 1-day performance
- -5.63%
- 1-year performance
- 105.84%
- Current drawdown (1Y)
- -9.40%
- CIK
- 0001991792
- CUSIP
- 156944100
- ISIN
- US1569441009
- Created
- 07/12/2025, 03:16:34
- Last update
- 24/09/2026, 15:27:35
Track CG Oncology Inc. with an AI analyst
See which prediction-market events move CGON, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
CG Oncology Eyes Bladder Cancer Breakthrough With Phase 3 Data, Q4 Filing Ahead
MarketBeat • STOCK • 10/06/2026, 05:02:38
CG Oncology, Inc. (CGON) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 09/06/2026, 19:52:11
CG Oncology Touts Cretostimogene Data, BLA Progress in Bladder Cancer Push
MarketBeat • STOCK • 07/06/2026, 19:06:19
CG Oncology Touts Bladder Cancer Data, Q4 Filing Plans at RBC Conference
MarketBeat • STOCK • 21/05/2026, 00:05:23
CG Oncology, Inc. (CGON) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 12/05/2026, 18:21:17
CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates
GlobeNewsWire • STOCK • 08/05/2026, 10:30:00
Wall Street Analysts Think CG Oncology, Inc. (CGON) Could Surge 29.78%: Read This Before Placing a Bet
Zacks Investment Research • STOCK • 05/05/2026, 12:55:38
CG Oncology, Inc. (CGON) Upgraded to Buy: Here's What You Should Know
Zacks Investment Research • STOCK • 01/05/2026, 15:02:16
CGON Stock Up 60.8% in Six Months: Here's What You Need to Know
Zacks Investment Research • STOCK • 15/04/2026, 13:10:21
This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know
The Motley Fool • STOCK • 21/03/2026, 19:05:08
CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates
GlobeNewsWire • STOCK • 27/02/2026, 09:30:00